



Amarin To Present at the 12th Annual BIO CEO & Investor Conference

DUBLIN and MYSTIC, Conn., Feb. 2 /PRNewswire-FirstCall/ -- Amarin Corporation plc (Nasdaq: [AMRN](#)) today announced that Dr. Declan Doogan, Interim Chief Executive Officer, is scheduled to present at the 12th Annual BIO CEO & Investor Conference on Monday, February 8th at 10:30am Eastern Time. This conference will be held at the Waldorf Astoria Hotel in New York City.

A live audio webcast of the presentation will be available at the following URL:

<http://www.veracast.com/webcasts/bio/ceoinvestor2010/56104283.cfm>.

A replay of the presentation will be available at the same URL for 30 days.

About Amarin

Amarin is a clinical-stage biopharmaceutical company with expertise in lipid science focused the treatment of cardiovascular disease. The Company's lead product candidate is AMR101 (ethyl icosapentate), has commenced enrollment of patients in two pivotal Phase 3 clinical trials for the treatment of patients with very high triglyceride levels and for the treatment of patients with high triglycerides with mixed dyslipidemia. Both of these Phase 3 trials were designed under Special Protocol Assessment (SPA) agreements with the U.S. Food and Drug Administration (FDA). Amarin also has next-generation lipid candidates under evaluation for preclinical development. For more information please visit www.amarincorp.com.

Contacts:

Investor Contact Information:
John F. Thero

Chief Financial Officer
In U.S.: +1 (860) 572 4979
investor.relations@amarincorp.com